Accounting Policies, by Policy (Policies)

9 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Investment, Policy [Policy Text Block]

Investment in iBio, Inc.- Restricted. The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. There was an impairment charge of $139 recorded in the three and nine months ended March 31, 2013. Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. In the fiscal year ended June 30, 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and has continued to have a trading price less than $0.88 through May 14, 2014. (See Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt). As of March 31, 2014, the Company has not sold any shares of the iBio Stock. As of May 14, 2014, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future.

Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share. Basic earnings per common share amounts are based on the weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, and warrants, subject to anti-dilution limitations using the treasury stock method and the assumed conversion shares of all potentially dilutive convertible notes payable subject to anti-dilution limitations using the if converted method.

The following options, warrants and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note Payable, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three and nine months ended March 31, 2014 and 2013:

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2014		2013		2014		2013
Anti-dilutive stock options		1,782,520		2,808,088		1,252,770		2,808,088
Anti-dilutive warrants		-		500,000		-		500,000
Potentially dilutive shares for convertible notes payable		8,230,769		8,230,769		8,230,769		8,230,769
Total anti-dilutive shares		10,013,289		11,538,857		9,483,539		11,538,857